Skip to main content
Insights into Imaging
Fig. 2 | Insights into Imaging

Fig. 2

From: Are radiologists ready to evaluate true response to immunotherapy?

Fig. 2

Ilustration shows mechanisms of action of immune check point inhibitors, including anti-CTLA-4 (ipilumumab), anti-PD-1 (nivolumab, pembrolizumab) and, anti-PD-L1 (atezolizumab) monoclonal antibodies (permission obtained from RSNA, Wang GX, Kurra V, Gainor JF, et al. (2017) Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics 37:2132–44)

Back to article page